Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical CancerCervical Cancer Metastatic; Cervical Cancer RecurrentNot yet recruitingPhase 22025-11-18NCT07143292

1 results · Page 1 of 1

Swipe the table sideways for more columns.

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
No products are listed yet.